You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
博濟醫藥(300404.SZ)簽訂甲磺酸帕拉德福韋片Ⅲ期臨牀研究委託開發合同
格隆匯 08-20 15:50

格隆匯8月20日丨博濟醫藥(300404.SZ)宣佈,2019年8月20日,公司作為乙方與西安新通作為甲方簽訂了《技術開發(委託)合同》。甲方作為“甲磺酸帕拉德福韋片”的藥品註冊申請人,授權委託乙方進行該項目Ⅲ期臨牀研究技術服務工作,合同總金額為人民幣9583萬元。

化藥1.1類新藥“甲磺酸帕拉德福韋片”為治療慢性乙型肝炎的新藥,西安新通為其藥品註冊申請人,前期已委託公司完成了該項目的Ⅱ期臨牀研究工作,達到了預期結果,順利進入Ⅲ期臨牀研究。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account